• 1
    Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61: 212-236.
  • 2
    Han M, Partin AW, Piantadosi S, et al. Era-specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol. 2001; 166: 416-419.
  • 3
    Zietman AL, Coen JJ, Dallow KC, Shipley WU. The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome. Int J Radiat Oncol Biol Phys. 1995; 32: 287-292.
  • 4
    Roehl KA, Han M, Ramos CG, et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004; 172: 910-914.
  • 5
    Eastham JA, Kelly WK, Grossfeld GD, et al. CALGB 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology. 2003; 62S: 55-62.
  • 6
    Fizazi K, Lesaunier F, Delva R, et al. Docetaxel-estramustine in high-risk localized prostate cancer: first results of the French Genitourinary Tumor Group phase III trial (GETUG 12) [abstract]. J Clin Oncol. 2011; 29( suppl 67). Abstract 4513.
  • 7
    Netto GJ, Eisenberger M, Epstein JI, et al. Interobserver variability in histologic evaluation of radical prostatectomy between central and local pathologists: findings of TAX3501 multinational clinical trial. Urology. 2011; 77: 1155-1160.
  • 8
    Kellokumpu-Lehtinen P, Hjelm-Eriksson M, Thellenberg-Karlsson C, et al. High toxicity in patients receiving adjuvant docetaxel plus hormone treatment after radical radiotherapy for high-risk prostate cancer: a preplanned safety report of SPCG 13 trial [abstract]. J Clin Oncol. 2011; 29( suppl 7). Abstract 63.
  • 9
    Montgomery B, Lavori P, Garzotto M, et al. Veterans Affairs Cooperative Studies Program study 553: chemotherapy after prostatectomy, a phase III randomized study of prostatectomy versus prostatectomy with adjuvant docetaxel for patients with high-risk, localized prostate cancer. Urology. 2008; 72: 474-480.
  • 10
    Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol-3,4,5-triphosphates. J Biol Chem. 1998; 273: 13375-13378.
  • 11
    Li L, Ittmann MM, Ayala G, et al. The emerging role of the PI3K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis. 2005; 8: 108-118.
  • 12
    Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007; 12: 9-22.
  • 13
    Yoshimoto M, Cutz JC, Nuin PA, et al. Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genet Cytogenet. 2006; 169: 128-137.
  • 14
    Yoshimoto M, Ludkovski O, Degrace D, et al. PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications. Genes Chromosomes Cancer. 2012; 51: 149-160.
  • 15
    Lotan TL, Gurel B, Sutcliffe S, et al. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high-risk surgical cohort of prostate cancer patients. Clin Cancer Res. 2011; 17: 6563-6573.
  • 16
    Bedolla R, Prihoda TJ, Kreisberg JI, et al. Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin Cancer Res. 2007; 13: 3860-3867.
  • 17
    Priulla M, Calastretti A, Bruno P, et al. Preferential chemosensitization of PTEN-mutated prostate cells by silencing the Akt kinase. Prostate. 2007; 67: 782-789.
  • 18
    Kibel AS, Rosenbaum E, Kattan MW, et al. Adjuvant weekly docetaxel for patients with high-risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol. 2007; 177: 1777-1781.
  • 19
    Gurel B, Iwata T, Koh CM, et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol. 2008; 21: 1156-1167.
  • 20
    Koh CM, Gurel B, Sutcliffe S, et al. Alterations in nucleolar structure and gene expression programs in prostatic neoplasia are driven by the MYC oncogene. Am J Pathol. 2011; 178: 1824-1834.
  • 21
    Tomlins SA, Mehra R, Rhodes DR, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005; 310: 644-648.
  • 22
    Furusato B, Tan SH, Young D, et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis. 2010; 13: 228-237.
  • 23
    Chaux A, Albadine R, Toubaji A, et al. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am J Surg Pathol. 2011; 35: 1014-1020.
  • 24
    van Leenders GJ, Boormans JL, Vissers CJ, et al. Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. Mod Pathol. 2011; 24: 1128-1138.
  • 25
    Roberts WW, Bergstralh EJ, Blute ML, et al. Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology. 2001; 57: 1033-1037.
  • 26
    Fedor HL, De Marzo AM. Practical methods for tissue microarray construction. Methods Mol Med. 2005; 103: 89-101.
  • 27
    Schultz L, Chaux A, Albadine R, et al. Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas. Am J Surg Pathol. 2011; 35: 1549-1556.
  • 28
    Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med. 1994; 331: 1259-1264.
  • 29
    Wang SI, Parsons R, Ittmann M. Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. Clin Cancer Res. 1998; 4: 811-815.
  • 30
    Pinhel IF, Macneill FA, Hills MJ, et al. Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer. Breast Cancer Res. 2010; 12: R76.
  • 31
    Vivanco I, Palaskas N, Tran C, et al. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell. 2007; 11: 555-569.
  • 32
    Mulholland DJ, Tran LM, Li Y, et al. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell. 2011; 19: 792-804.
  • 33
    Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008; 8: 976-990.
  • 34
    Kurosumi M, Tabei T, Sano M, et al. Relationship between the signal ratios of HER-2/CEP17 and c-MYC/CEP17 and the pathological response of neoadjuvant therapy using docetaxel and trastuzumab in breast cancer. Mol Med Rep. 2008; 1: 71-75.
  • 35
    Salter KH, Acharya CR, Walters KS, et al. An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. PLoS One. 2008; 3: e1908.
  • 36
    Geng H, Rademacher BL, Pittsenbarger J, et al. ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21. Cancer Res. 2010; 70: 3239-3248.